Use of BAFF to treat Th2-mediated conditions

Details for Australian Patent Application No. 2006209237 (hide)

Owner Biogen Idec MA Inc. The Garvan Institute of Medical Research

Inventors Mackay, Fabienne; Mackay, Charles; Kalled, Susan

Agent Cullens

Pub. Number AU-B-2006209237

PCT Pub. Number WO2006/081516

Priority 60/648,098 28.01.05 US

Filing date 27 January 2006

Wipo publication date 3 August 2006

Acceptance publication date 24 June 2010

International Classifications

C07K 16/24 (2006.01) Immunoglobulins, e.g. monoclonal or polyclonal antibodies

A61K 38/19 (2006.01) Medicinal preparations containing peptides - Cytokines

Event Publications

23 August 2007 PCT application entered the National Phase

  PCT publication WO2006/081516 Priority application(s): WO2006/081516

24 June 2010 Application Accepted

  Published as AU-B-2006209237

21 October 2010 Standard Patent Sealed

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2006209239-Hydrophilic biocompatible adhesive formulations and uses

2006209231-Systems, methods, and software for integration of case law, legal briefs, and/ or litigation documents into law firm workflow